PURPOSE: To assess the effect of 18 hour (h) 50% xenon (Xe) inhalation at normothermia (NT, 38.5°C) or hypothermia (HT, 33.5°C) on mean arterial blood pressure (MABP), inotropic support and heart rate (HR) following an induced perinatal global hypoxic-ischaemic insult (HI) in newborn pigs. METHODS: Newborn pigs ventilated under inhalational anaesthesia, following a 45 min HI (inhaled oxygen fraction reduced until amplitude integrated electroencephalogram was less than 7 μV), were randomised to three Xe (n = 45) (50% Xe 18 h with NT, HT 12 h or HT 24 h) or three non-Xe groups (n = 53) (0% Xe with NT, HT 12 h or HT 24 h) under otherwise identical conditions. We measured MABP and HR every minute. Hypotension (MABP <40 mmHg) was treated sequentially with 2 × 10 mL/kg saline, dopamine, norepinephrine and hydrocortisone if required. RESULTS: Xe maintained higher MABP during HT (5.1 mmHg, 95% CI 2.34, 7.89), rewarming (10.1 mmHg, 95% CI 6.26, 13.95) and after cessation (4.1 mmHg, 95% CI 0.37, 7.84) independent of HT, inotropic support and acidosis. Xe reduced the duration of inotropic support by 12.6 h (95% CI 5.5, 19.73). Inotropic support decreased the HR reduction induced by HT from 9 to 5 bpm/°C during cooling and from 10-7 to 4-3 bpm/°C during rewarming. There was no interaction between Xe, HT, inotropic support and acidosis. Xe during HT cleared lactate faster; 3 h post-HI median (IQR) values of (Xe HT) 2.8 mmol/L (0.9, 3.1) vs. (HT) 5.9 mmol/L (2.5, 7.9), p = 0.0004. CONCLUSION: Xe maintained stable blood pressure, thereby reducing the inotropic support requirements during and after administration independently of induced HT-current neonatal encephalopathy treatment. Xe may offer haemodynamic benefits in clinical neuroprotection studies.
PURPOSE: To assess the effect of 18 hour (h) 50% xenon (Xe) inhalation at normothermia (NT, 38.5°C) or hypothermia (HT, 33.5°C) on mean arterial blood pressure (MABP), inotropic support and heart rate (HR) following an induced perinatal global hypoxic-ischaemic insult (HI) in newborn pigs. METHODS: Newborn pigs ventilated under inhalational anaesthesia, following a 45 min HI (inhaled oxygen fraction reduced until amplitude integrated electroencephalogram was less than 7 μV), were randomised to three Xe (n = 45) (50% Xe 18 h with NT, HT 12 h or HT 24 h) or three non-Xe groups (n = 53) (0% Xe with NT, HT 12 h or HT 24 h) under otherwise identical conditions. We measured MABP and HR every minute. Hypotension (MABP <40 mmHg) was treated sequentially with 2 × 10 mL/kg saline, dopamine, norepinephrine and hydrocortisone if required. RESULTS:Xe maintained higher MABP during HT (5.1 mmHg, 95% CI 2.34, 7.89), rewarming (10.1 mmHg, 95% CI 6.26, 13.95) and after cessation (4.1 mmHg, 95% CI 0.37, 7.84) independent of HT, inotropic support and acidosis. Xe reduced the duration of inotropic support by 12.6 h (95% CI 5.5, 19.73). Inotropic support decreased the HR reduction induced by HT from 9 to 5 bpm/°C during cooling and from 10-7 to 4-3 bpm/°C during rewarming. There was no interaction between Xe, HT, inotropic support and acidosis. Xe during HT cleared lactate faster; 3 h post-HI median (IQR) values of (Xe HT) 2.8 mmol/L (0.9, 3.1) vs. (HT) 5.9 mmol/L (2.5, 7.9), p = 0.0004. CONCLUSION:Xe maintained stable blood pressure, thereby reducing the inotropic support requirements during and after administration independently of induced HT-current neonatal encephalopathy treatment. Xe may offer haemodynamic benefits in clinical neuroprotection studies.
Authors: David B Seder; Gilles L Fraser; Tracy Robbins; Laurel Libby; Richard R Riker Journal: Intensive Care Med Date: 2009-10-22 Impact factor: 17.440
Authors: Elavazhagan Chakkarapani; John Dingley; Xun Liu; Nicholas Hoque; Kristian Aquilina; Helen Porter; Marianne Thoresen Journal: Ann Neurol Date: 2010-09 Impact factor: 10.422
Authors: Seetha Shankaran; Abbot R Laptook; Richard A Ehrenkranz; Jon E Tyson; Scott A McDonald; Edward F Donovan; Avroy A Fanaroff; W Kenneth Poole; Linda L Wright; Rosemary D Higgins; Neil N Finer; Waldemar A Carlo; Shahnaz Duara; William Oh; C Michael Cotten; David K Stevenson; Barbara J Stoll; James A Lemons; Ronnie Guillet; Alan H Jobe Journal: N Engl J Med Date: 2005-10-13 Impact factor: 91.245
Authors: Rolf Rossaint; Matthias Reyle-Hahn; Jochen Schulte Am Esch; Jens Scholz; Philippe Scherpereel; Benoit Vallet; Francesco Giunta; Monica Del Turco; Wilhelm Erdmann; Rob Tenbrinck; Alfons F Hammerle; Peter Nagele Journal: Anesthesiology Date: 2003-01 Impact factor: 7.892
Authors: Sarah Devroe; Jurgen Lemiere; Marc Van de Velde; Marc Gewillig; Derize Boshoff; Steffen Rex Journal: Trials Date: 2015-03-04 Impact factor: 2.279
Authors: Thomas Alderliesten; Laurent M A Favie; Robert W Neijzen; Volker Auwärter; Cora H A Nijboer; Roland E J Marges; Carin M A Rademaker; Jürgen Kempf; Frank van Bel; Floris Groenendaal Journal: PLoS One Date: 2014-12-02 Impact factor: 3.240
Authors: Kei Hayashida; Santiago J Miyara; Koichiro Shinozaki; Ryosuke Takegawa; Tai Yin; Daniel M Rolston; Rishabh C Choudhary; Sara Guevara; Ernesto P Molmenti; Lance B Becker Journal: Front Med (Lausanne) Date: 2021-01-14
Authors: Massimo Antonelli; Marc Bonten; Maurizio Cecconi; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J R Curtis; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Salvatore M Maggiore; Jordi Mancebo; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2013-01-22 Impact factor: 17.440
Authors: Youness Tolaymat; Sylvain Doré; Hudson W Griffin; Susana Shih; Mary E Edwards; Michael D Weiss Journal: Front Pediatr Date: 2020-01-27 Impact factor: 3.418